Cargando…

Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()

Acquired resistance and intrinsic to sorafenib therapy represents a major hurdle in improving the management of advanced hepatocellular carcinoma (HCC), which has been recently shown to be associated with the emergence of liver cancer stem cells (CSCs). However, it remains largely unknown whether an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shanshan, Cai, Long, Zhang, Fengwei, Shang, Xuechai, Xiao, Rong, Zhou, Hongjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036423/
https://www.ncbi.nlm.nih.gov/pubmed/32092673
http://dx.doi.org/10.1016/j.tranon.2020.01.002
_version_ 1783500214607282176
author Wang, Shanshan
Cai, Long
Zhang, Fengwei
Shang, Xuechai
Xiao, Rong
Zhou, Hongjuan
author_facet Wang, Shanshan
Cai, Long
Zhang, Fengwei
Shang, Xuechai
Xiao, Rong
Zhou, Hongjuan
author_sort Wang, Shanshan
collection PubMed
description Acquired resistance and intrinsic to sorafenib therapy represents a major hurdle in improving the management of advanced hepatocellular carcinoma (HCC), which has been recently shown to be associated with the emergence of liver cancer stem cells (CSCs). However, it remains largely unknown whether and how histone posttranslational modifications, especially H3K27me3, are causally linked to the maintenance of self-renewal ability in sorafenib-resistant HCC. Here, we found that NOTCH1 signaling was activated in sorafenib-resistant HCC cells and NOTCH1 activation conferred hepatoma cells sorafenib resistance through enhanced self-renewal and tumorigenecity. Besides, the overexpression of EZH2 was required for the emergence of cancer stem cells following prolonged sorafenib treatment. As such, modulating EZH2 expression or activity suppressed activation of NOTCH1 pathway by elevating the expression of NOTCH1-related microRNAs, hsa-miR-21-5p and has-miR-26a-1-5p, via H3K27me3, and consequently weakened self-renewal ability and tumorigenecity and restored the anti-tumor effects of sorafenib. Overall, our results highlight the role of EZH2/NICD1 axis, and also suggest that EZH2 and NOTCH1 pathway are rational targets for therapeutic intervention in sorafenib-resistant HCC.
format Online
Article
Text
id pubmed-7036423
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-70364232020-03-02 Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()() Wang, Shanshan Cai, Long Zhang, Fengwei Shang, Xuechai Xiao, Rong Zhou, Hongjuan Transl Oncol Original article Acquired resistance and intrinsic to sorafenib therapy represents a major hurdle in improving the management of advanced hepatocellular carcinoma (HCC), which has been recently shown to be associated with the emergence of liver cancer stem cells (CSCs). However, it remains largely unknown whether and how histone posttranslational modifications, especially H3K27me3, are causally linked to the maintenance of self-renewal ability in sorafenib-resistant HCC. Here, we found that NOTCH1 signaling was activated in sorafenib-resistant HCC cells and NOTCH1 activation conferred hepatoma cells sorafenib resistance through enhanced self-renewal and tumorigenecity. Besides, the overexpression of EZH2 was required for the emergence of cancer stem cells following prolonged sorafenib treatment. As such, modulating EZH2 expression or activity suppressed activation of NOTCH1 pathway by elevating the expression of NOTCH1-related microRNAs, hsa-miR-21-5p and has-miR-26a-1-5p, via H3K27me3, and consequently weakened self-renewal ability and tumorigenecity and restored the anti-tumor effects of sorafenib. Overall, our results highlight the role of EZH2/NICD1 axis, and also suggest that EZH2 and NOTCH1 pathway are rational targets for therapeutic intervention in sorafenib-resistant HCC. Neoplasia Press 2020-02-22 /pmc/articles/PMC7036423/ /pubmed/32092673 http://dx.doi.org/10.1016/j.tranon.2020.01.002 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Wang, Shanshan
Cai, Long
Zhang, Fengwei
Shang, Xuechai
Xiao, Rong
Zhou, Hongjuan
Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
title Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
title_full Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
title_fullStr Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
title_full_unstemmed Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
title_short Inhibition of EZH2 Attenuates Sorafenib Resistance by Targeting NOTCH1 Activation-Dependent Liver Cancer Stem Cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma()()
title_sort inhibition of ezh2 attenuates sorafenib resistance by targeting notch1 activation-dependent liver cancer stem cells via notch1-related micrornas in hepatocellular carcinoma()()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036423/
https://www.ncbi.nlm.nih.gov/pubmed/32092673
http://dx.doi.org/10.1016/j.tranon.2020.01.002
work_keys_str_mv AT wangshanshan inhibitionofezh2attenuatessorafenibresistancebytargetingnotch1activationdependentlivercancerstemcellsvianotch1relatedmicrornasinhepatocellularcarcinoma
AT cailong inhibitionofezh2attenuatessorafenibresistancebytargetingnotch1activationdependentlivercancerstemcellsvianotch1relatedmicrornasinhepatocellularcarcinoma
AT zhangfengwei inhibitionofezh2attenuatessorafenibresistancebytargetingnotch1activationdependentlivercancerstemcellsvianotch1relatedmicrornasinhepatocellularcarcinoma
AT shangxuechai inhibitionofezh2attenuatessorafenibresistancebytargetingnotch1activationdependentlivercancerstemcellsvianotch1relatedmicrornasinhepatocellularcarcinoma
AT xiaorong inhibitionofezh2attenuatessorafenibresistancebytargetingnotch1activationdependentlivercancerstemcellsvianotch1relatedmicrornasinhepatocellularcarcinoma
AT zhouhongjuan inhibitionofezh2attenuatessorafenibresistancebytargetingnotch1activationdependentlivercancerstemcellsvianotch1relatedmicrornasinhepatocellularcarcinoma